Michael J. Hall, MD, MS
- Request Appointment
- Education, Training & Credentials
- Patient Stories
- Research Profile
Director, Gastrointestinal Risk Assessment
- Gastrointestinal oncology/medical oncology
- Cancer risk assessment for cancers of the gastrointestinal tract
- Cancer risk assessment for endocrine cancers and genitourinary cancers
I am a GI oncologist and a clinical cancer geneticist, and I have found over the years that my strongest skills are in helping my patients and their families to understand the complicated risks of cancer screening, surgery and treatment, to weigh the different options for treatment, and finally to develop a plan that is both in line with cutting edge research but also with their personal needs and preferences for their health and their lives. In cancer medicine, there is no longer a one size fits all approach, and in my practice I strive to build on my patients’ unique strengths and to further bring the multi-faceted expertise of my colleagues at Fox Chase and my colleagues nationally to offer each of my patients the best care I possibly can.
- MS, Health Studies, University of Chicago Medical Center, Chicago, IL, 2006
- MD, Columbia College Physicians & Surgeons, New York, NY, 1999
- BA, French Literature, Columbia University, New York, NY, 1993
- Board Certified in Medical Oncology
- Board Certified in Hematology
- Pennsylvania Medical License
- American Cancer Society
- American Society of Clinical Oncology
- Research Review Committee, Fox Chase Cancer Center
Honors & Awards
- Mentored Research Scholar Grant, American Cancer Society, 2007
- Young Investigator Award, American Society of Clinical Oncology, 2006
- Merit Award, American Society of Clinical Oncology, 2003-2005
- Honorary Alpha Omega Alpha, University of Chicago, 2004
- Excellence in Teaching Award, Harvard Medical School, 2001
- Alpha Omega Alpha, Columbia College of Physicians/Surgeons, 1999
Not many people can say they "grew up at Fox Chase," but Alan Stachura can. When he was only six years old, his mother was diagnosed with invasive breast cancer. When she arrived at Fox Chase Cancer Center to meet with medical oncologist Paul F. Engstrom, MD, she learned that the disease had already spread to her bones.
For over nine months, Sharifah Furson, a registered nurse at a university hospital in Philadelphia, experienced bloating, pain while using the bathroom and abdominal discomfort. When she noticed blood in her stool in December 2014, she immediately went to her doctor. “I thought my symptoms were caused by stress or my diet, but when I saw blood I knew to seek medical attention,” says Sharifah.
Like many young women Brooke Fuller is a busy working mother and wife. Brooke, who enjoys working as a floral designer, and her husband, Scott, are parents to one son, Pierce, who turned four in 2015. In January, 2014, at age 30, Brooke experienced unexplained weight loss and rectal bleeding. The last thing she attributed this to was cancer.
Maintaining an active lifestyle was always a priority for Todd Jackman, a professor of biology at Villanova University. He enjoyed running and was training for a half-marathon with his son. In the spring of 2014, he started experiencing bleeding which he attributed to hemorrhoids. Six months had passed with this ongoing symptom, and his wife urged him to go to the doctor.“I went to see my family doctor, who performed a physical,” recalls Todd.
- Hereditary cancer risk for gastrointestinal cancers
- Lynch syndrome, microsatellite instability, polyposis syndromes, DNA repair
- Genetic and genomic testing in cancer patients
- Communication of genetic risk information to patients and physicians
- Health disparities related to genetic and genomic testing
- Genetic basis of cancer, especially cancer in young adults
The Risk Assessment Program at Fox Chase looks at your personal and possible inherited genetic factors that may put you at higher possibility for getting cancer. We comprehensively examine your profile for all cancer types, including — but not limited to — breast cancer, ovarian cancer, gastrointestinal cancers, prostate cancer, and melanoma. Knowing your risk helps you learn what you can do to lower your chances of getting cancer.
The Department of Clinical Genetics is built on the success of Fox Chase's Margaret Dyson Family Risk Assessment Program (now Risk Assessment Program), which Dr. Mary Daly began in 1991. A high-risk screening clinic was developed for individuals with a family history of breast or ovarian cancer. In addition to the clinic, genetic counseling was provided for both high risk and breast and ovarian cancer patients. As the clinic developed, it became clear that it was important to provide consultations for biopsy findings that put women at increased risk. Since then, Fox Chase has expanded risk assessment services to those at high risk for all cancers.
PA-C –Physician Assistant
Intake Specialist/Administrative Assistant
Yana Chertock, MA
Research Study Assistant
Michelle Savage, MS, LCGC
Cancer Genetic Counselor
Andrea Forman, MS, LCGC
Cancer Genetic Counselor
Kim Rainey, MS, LCGC
Cancer Genetic Counselor
1. Hall MJ. Conflicted Confidence: Academic Oncologists' Views on Multiplex Pharmacogenomic Testing. J Clin Oncol. 2014 Mar 24. PubMed
2. Hall MJ, Manne SL, Winkel G, Chung DS, Weinberg DS, Meropol NJ. Effects of a decision support intervention on decisional conflict associated with microsatellite instability testing. Cancer Epidemiol Biomarkers Prev 2011;20(2):249-54. PubMed
3. Hall MJ, Ruth K, Giri VN. Predictors of compliance with age-appropriate colorectal cancer screening in men enrolled in a prostate cancer screening program. Cancer 2012 Jan 15;118(2):478-84.
4. Hall MJ, Manne SL, Myers RE, Keenan EM, Balshem AM, Weinberg DS. Association of knowledge and race to gene environment risk assessment (GERA) testing for colorectal cancer Genome Med 2012;4(11):92 [epub ahead of print] PMID: 23194586.
5. Matro JM, Ruth KJ, Wong YN, McCully KC, Rybak CM, Meropol NJ, Hall MJ. Cost-sharing and hereditary cancer risk: predictors of willingness-to-pay for genetic testing. J Genet Couns. 2014 May 6.
6. Hall MJ, Herda MM, Handorf EA, Rybak CC, Keleher CA, Siemon M, Daly MB. Direct access to universal mismatch repair (MMR) screening results for Lynch syndrome (LS) via electronic personal health record (ePHR):A feasibility study.Genet Med. 2014 May 1.
7. Bradbury AR, Patrick-Miller L, Long J, Stopfer J, Forman A, Rybak C, Mattie K, ChungW, Churpek J, Clark-Farengo D, Daly M, Digiovanni L, Fetzer D, Ganschow P, Grana G, Gulden C, Hall MJ, Kohler L, Lorenz R, Maxwell K, Merrill S, Montgomery S, Nathanson K, Nielsen S, Olopade O, Rainey K, Seelaus C, Domchek S. Development of a tiered and binned counseling model for informed consent in the era of multiplex testing for cancer susceptibility Genet Med. 2014 Oct 9. PubMed
8. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014 Sep;12(9):1339-1346. PubMed
9. Boland, PM, Ruth K, Matro JM, Rainey KL, Fang CY, Wong YN, Daly MB, Hall, MJ.
Genetic counselors’ (GC) knowledge, awareness, and understanding of clinical next-generation sequencing (NGS) genomic testing. Clinical Genetics 2015. PubMed
10. Hall MJ, Forman AD, Montgomery SV, Rainey KL, Daly MB. Understanding patient and provider perceptions and expectations of genomic medicine. J Surg Oncol 2014.
11. Hall MJ, Innocent J, Rybak CM, Veloski C, Scott WJ, Wu H, Ridge JA, Hoffman JP, Borghaei H, Turaka A, Daly MB. Case Report: Bilateral granulosa cell carcinoma: A novel malignant manifestation of MEN1 syndrome associated with a rare intronic deletion. Appl Clin Gen 2014. PubMed
12. Meyer JE, Cohen SJ, Ruth KJ, Sigurdson E, Hall MJ. Young age increases risk of lymph node positivity in early stage rectal cancer. (Accepted Sept 2015, JNCI).
13. Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Hall MJ, Golemis EA, Giri VN, Daly MB. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. (Accepted Sept 2015, Oncotarget NIHMSID # 722094).
14. Arora S, Yan H, Cho I, Fan HY, Luo B, Gai X, Bodian DL, Vockley JG, Zhou Y, Handorf E, Egleston B, Andrake M, Nicolas E, Serebriiskii IG, Yen TJ, Hall MJ, Golemis EA, Enders GH. Genetic Variants That Presdispose to DNA Double-strand Breaks in Lymphocytes from a Subset of Patients With Familial Colorectal Carcinomas. Gastroenterology. 2015 Sep 4. pii: S0016-5085(15)01259-7. doi: 10.1053/j.gastro.2015.08.052. [Epub ahead of print].
15. Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall MJ, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, Terdiman J, Shuttlesworth GA, Lynch PM, Hampel H, Lynch HT, Jenkins MA, Olopade OI, Kupfer SS. Mutation spectrum and risk of colorectal cancer in African American families with Lynch Syndrome. Gastroenterology. 2015 Aug 3. pii: S0016-5085(15)01084-7. doi: 10.1053/j.gastro.2015.07.052. [Epub ahead of print].